サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1752832

経口タンパク質・ペプチドの世界市場：有効成分別、製剤タイプ別、デリバリー技術別、治療適応症別、地域別、機会、予測、2018年～2032年

Global Oral Proteins and Peptides Assessment, By Active Ingredient, By Formulation Type, By Delivery Technology, By Therapeutic Indication, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 245 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.06円
経口タンパク質・ペプチドの世界市場：有効成分別、製剤タイプ別、デリバリー技術別、治療適応症別、地域別、機会、予測、2018年～2032年
出版日: 2025年06月20日
発行: Markets and Data
ページ情報: 英文 245 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の経口タンパク質・ペプチド市場は、予測期間2025-2032年のCAGRが13.66％となり、2024年の66億7,000万米ドルから2032年には185億8,000万米ドルに成長すると予測されています。経口タンパク質とペプチドは、注射の代わりに錠剤やカプセルの形で口から摂取する治療用生体分子です。

経口ペプチドとタンパク質は、より優れた医療デリバリー技術と、利用しやすい治療ソリューションに対する患者の関心の高まりが相まって、世界中で大幅な市場成長を遂げています。経口タンパク質・ペプチド治療は、注射薬よりも簡便であるため、慢性疾患を管理する患者にとって好ましい選択肢となっています。がんや胃腸障害と並んで糖尿病の治療においても、経口ペプチド製剤は、より良い治療成績と薬物吸収の改善をもたらすため、大きな利益をもたらしています。

革新的なカプセル化技術と浸透促進剤の開発により、長い間続いた栄養吸収の困難さと酵素分解の問題を解決することに成功しました。主要製薬企業は研究開発に多額の資金を投入して製品ラインを拡大する一方、バイオテクノロジー企業との戦略的提携を確立して市場参入を加速させています。

北米と欧州の医療システムは、その強力なインフラと医療研究に多額の投資を行う能力により、市場をリードしています。アジア太平洋地域の医療領域は、医療意識の高まりと同地域における投資活動の活発化により、有望な成長見通しを示しています。

慢性疾患は増加の一途をたどっており、医療産業は個別化医療提供システムへと移行しているため、規制の複雑さや製造上の課題にもかかわらず、市場の成長は続くと思われます。例えば、2023年にはEli Lilly and CompanyがDice Therapeuticsを24億米ドルで買収し、経口ペプチド治療、特に自己免疫疾患を治療するIL-17阻害剤に深い関心を示しています。業界は、患者が注射薬よりも便利だと感じる新しい治療オプションへの動きを示しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の経口タンパク質・ペプチドの展望、2018年～2032年

  • 市場規模分析と予測
    • 金額別
  • 市場シェア分析と予測
    • 有効成分別
      • セマグルチド
      • リナクロチド
      • カルシトニン
      • オクトレオチド
      • その他
    • 製剤タイプ別
      • 錠剤
      • カプセル
      • 経口懸濁液/溶液
    • デリバリー技術別
      • 腸溶コーティングシステム
      • ナノ粒子/キャリアベースデリバリー
      • 粘膜付着技術
      • その他
    • 治療適応症別
      • 糖尿病
      • 胃腸障害
      • 骨代謝疾患
      • 内分泌疾患
      • 遺伝性疾患・希少疾患
      • その他
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別の市場シェア分析（上位5社・その他 - 金額別、2024年）
  • 2024年の市場マップ分析
    • 有効成分別
    • 製剤タイプ別
    • デリバリー技術別
    • 治療適応症別
    • 地域別

第6章 北米の経口タンパク質・ペプチドの展望、2018年～2032年

  • 市場規模分析と予測
    • 金額別
  • 市場シェア分析と予測
    • 有効成分別
      • セマグルチド
      • リナクロチド
      • カルシトニン
      • オクトレオチド
      • その他
    • 製剤タイプ別
      • 錠剤
      • カプセル
      • 経口懸濁液/溶液
    • デリバリー技術別
      • 腸溶コーティングシステム
      • ナノ粒子/キャリアベースデリバリー
      • 粘膜付着技術
      • その他
    • 治療適応症別
      • 糖尿病
      • 胃腸障害
      • 骨代謝疾患
      • 内分泌疾患
      • 遺伝性疾患・希少疾患
      • その他
    • 国別シェア
      • 米国
      • カナダ
      • メキシコ
  • 国別市場評価
    • 米国の経口タンパク質・ペプチドの展望、2018年～2032年
      • 市場規模分析と予測
      • 市場シェア分析と予測
    • カナダ
    • メキシコ

第7章 欧州の経口タンパク質・ペプチドの展望、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の経口タンパク質・ペプチドの展望、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の経口タンパク質・ペプチドの展望、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの経口タンパク質・ペプチドの展望、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 サプライチェーン分析

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

第15章 PESTLE分析

第16章 価格分析

第17章 市場力学

  • 市場促進要因
  • 市場の課題

第18章 市場動向と発展

第19章 規制の枠組み

  • 規制承認シナリオ
  • 規制当局の承認

第20章 特許の情勢

第21章 ケーススタディ

第22章 競合情勢

  • 市場リーダー上位5社の競合マトリックス
  • 上位5社のSWOT分析
  • 上位10社の主要企業の情勢
    • Novo Nordisk A/S
    • Pfizer Inc.
    • AbbVie Inc.
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.
    • Biocon Limited
    • Synergy Pharmaceuticals Inc.
    • Oramed Pharmaceuticals Inc.
    • Acadia Pharmaceuticals Inc.
    • Proxima Concepts Limited

第23章 戦略的提言

第24章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 3. Global Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 4. Global Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 5. Global Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 6. Global Oral Proteins and Peptides Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 9. North America Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 10. North America Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 11. North America Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 12. North America Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 15. United States Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 16. United States Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 17. United States Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 18. Canada Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 20. Canada Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 21. Canada Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 22. Canada Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 23. Mexico Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 25. Mexico Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 26. Mexico Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 27. Mexico Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 28. Europe Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 30. Europe Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 31. Europe Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 32. Europe Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 33. Europe Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 36. Germany Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 37. Germany Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 38. Germany Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 39. France Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 41. France Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 42. France Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 43. France Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 44. Italy Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 46. Italy Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 47. Italy Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 48. Italy Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 49. United Kingdom Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 51. United Kingdom Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 52. United Kingdom Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 53. United Kingdom Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 54. Russia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 56. Russia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 57. Russia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 58. Russia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 59. Netherlands Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 61. Netherlands Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 62. Netherlands Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 63. Netherlands Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 64. Spain Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 66. Spain Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 67. Spain Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 68. Spain Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 69. Turkey Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 71. Turkey Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 72. Turkey Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 73. Turkey Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 74. Poland Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 76. Poland Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 77. Poland Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 78. Poland Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 79. South America Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. South America Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 81. South America Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 82. South America Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 83. South America Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 84. South America Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
  • Figure 85. Brazil Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Brazil Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 87. Brazil Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 88. Brazil Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 89. Brazil Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 90. Argentina Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Argentina Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 92. Argentina Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 93. Argentina Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 94. Argentina Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 95. Asia-Pacific Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 97. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 98. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 99. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 100. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
  • Figure 101. India Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 103. India Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 104. India Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 105. India Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 106. China Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. China Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 108. China Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 109. China Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 110. China Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 111. Japan Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 112. Japan Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 113. Japan Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 114. Japan Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 115. Japan Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 116. Australia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 117. Australia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 118. Australia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 119. Australia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 120. Australia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 121. Vietnam Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 122. Vietnam Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 123. Vietnam Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 124. Vietnam Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 125. Vietnam Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 126. South Korea Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. South Korea Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 128. South Korea Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 129. South Korea Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 130. South Korea Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 131. Indonesia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Indonesia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 133. Indonesia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 134. Indonesia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 135. Indonesia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 136. Philippines Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Philippines Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 138. Philippines Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 139. Philippines Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 140. Philippines Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 141. Middle East & Africa Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 143. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 144. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 145. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 146. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 149. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 150. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 151. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 152. UAE Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 154. UAE Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 155. UAE Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 156. UAE Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 157. South Africa Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
  • Figure 159. South Africa Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
  • Figure 160. South Africa Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
  • Figure 161. South Africa Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
  • Figure 162. By Active Ingredient Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Formulation Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Delivery Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Therapeutic Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13420

Global oral proteins and peptides market is projected to witness a CAGR of 13.66% during the forecast period 2025-2032, growing from USD 6.67 billion in 2024 to USD 18.58 billion in 2032. Oral proteins and peptides are therapeutic biomolecules taken through the mouth in the form of tablets and capsules instead of injections.

Oral peptides and proteins are experiencing substantial market growth worldwide because of better medical delivery techniques combined with growing patient interest in accessible therapeutic solutions. Oral protein and peptide treatment has become the preferred option for patients who manage chronic conditions because of its simplicity over injectable medications. The treatment of diabetes alongside cancer and gastrointestinal disorders benefits greatly from oral peptide formulations because they provide better therapeutic outcomes and improved drug absorption.

The development of innovative encapsulation technologies and penetration enhancers has successfully resolved nutritional absorption difficulties and enzymatic degradation problems that lasted for a long time. Leading pharmaceutical companies dedicate substantial funding to research and development to grow their product lines while establishing strategic alliances with biotechnology organizations to speed up market entry.

The healthcare systems of North America and Europe lead the market because of their strong infrastructure and their ability to invest heavily in medical research. The healthcare domain of the Asia-Pacific region shows promising growth prospects because of increased healthcare awareness combined with growing investment activities in the region.

Market growth will continue despite regulatory complexity and manufacturing challenges since chronic diseases keep increasing, and the healthcare industry is moving toward personalized medicine delivery systems. For instance, in 2023, Eli Lilly and Company purchased Dice Therapeutics for USD 2.4 billion to demonstrate their deep interest in oral peptide therapy, especially for IL-17 inhibitors, which treat autoimmune conditions. The industry demonstrates a movement toward new treatment options, which patients find more convenient than injectable drugs.

Rising Prevalence of Chronic Disease Boosts Market Demand

The rising prevalence of chronic disease is increasing due to diabetes, cardiovascular disorders, obesity, and gastrointestinal conditions, which will boost the need for oral proteins and peptides as a more user-friendly treatment alternative to injections. The healthcare system faces a growing disease burden because of modern sedentary living habits, which are paired with unhealthy eating patterns and rising stress levels while dealing with an aging population. For instance, according to the International Diabetes Federation, about 539 million adults are currently dealing with diabetes, and the number is expected to increase to 853 million by the year 2050. The growing diabetes epidemic supports the increased market sales of oral peptide therapeutics such as GLP-1 agonists.

Furthermore, cancer and autoimmune diseases are also less common, and advanced biologic treatments are needed as the second line of treatment. With compliance factors encountered with injectable biologics, traditional injectable alternatives are an attractive option for continuous, long-term treatment. Health providers and governments are putting patients first, which is driving R&D to deliver oral protein more quickly. These trends quickly require innovative, non-invasive therapies to prevent chronic disease and boost market demand effectively.

Advancement in Drug Discovery Technology to Uplift Market Expansion

Expected growth in the oral proteins and peptides market will be fueled by modern advancements in drug discovery techniques. New technologies such as AI-enabled drug design, high-throughput screening, and computational modeling support the identification of peptides closer to any notion of stability and bioavailability. New delivery systems such as nanoparticle carriers and permeation enhancers allow peptides to overcome traditional challenges, including poor absorption and enzymatic degradation after oral administration. Formulation technologies such as enteric coatings and protease inhibitors improve oral bioavailability as well. In addition, biotech companies are also tapping into unique CRISPR and mRNA platforms to develop next-generation peptide therapeutics.

Additionally, key players are focusing on advanced technology for the development of oral proteins and peptides. For instance, in June 2024, Biora Therapeutics, Inc. announced the results of preclinical trials of its latest technology, the BioJet Systemic Oral Delivery Platform, at the Next Gen Peptide Formulation & Delivery conference. This technology is used as an ingestible device designed to transit through the digestive system and activate in the small intestine. Such advanced technology increased the potential of oral protein and peptides therapies in targeted delivery, by providing alternatives to injections and expanding the uses of various medical treatments.

Tablets Hold the Largest Market Share of the Oral Protein and Peptides Market

The oral protein and peptides market is dominated by tablets due to limitations of the oral form of protein and peptides, so they are most common. Tablets' unique solid dosage form allows a lot more convenience in administration, provides longer shelf stability than liquids or powders, with precise dosage, and if needed, doesn't need to be refrigerated. Innovations (technologies) in formulating biomolecules (enteric and controlled release formulation technologies) have impacted biologically sensitive biomolecules and their capability to produce sensitive biomolecules and novel forms of sensitive biologic oral delivery. Tablets are also less expensive to manufacture and ship than a vial or liquid drug, which makes them the most developed and accepted delivery form for pharmaceutical companies, because there are accepted manufacturing, distribution, and marketing pathways for tablets. While there are some alternative formats also available today (i.e., capsules, oral films), tablets or solid dosage forms are the historically most trusted and accepted dosage form for chronic treatments (demand for protein and peptide delivery by the oral route).

For instance, in April 2025, Merck & Co., Inc. announced that peptide drugs may soon be available in convenient oral tablet form through a USD 493 million licensing deal with Austria-based drug delivery technology maker Cyprumed.

North America Dominates the Oral Proteins and Peptides Market

North America is dominant in the global oral proteins and peptides market due to its cutting-edge healthcare infrastructure, strong research and development capabilities, and high demand for advanced biological therapies. The established pharmaceutical sector, along with flexible regulations in this region, allows quick development and market entry of novel oral protein-based medical solutions. The increasing occurrence of chronic diseases, especially diabetes and gastrointestinal disorders, creates a growing market for convenient oral peptide treatment options. North America strengthens its market leadership through major biotechnology investments and the rising popularity of non-invasive drug delivery methods. The region remains dominant in the emerging oral proteins and peptides industry through continuous drug formulation technology combined with expanding clinical applications.

Additionally, most of the pharmaceutical companies' headquarters are in North America. Along with the key industry players, numerous medical research organizations are propelling market growth by launching new products or innovative research. For instance, in February 2024, Johnson & Johnson Services, Inc., presented phase 2b FRONTIER 1 trial results for JNJ-2113, the first oral peptides under development for the treatment of moderate to severe plaque psoriasis (PsO).

Impact of U.S. Tariffs on Oral Proteins and Peptides Market

The global protein and peptide market shows significant disruptions due to the U.S. tariff implementation because it affects supply networks and generates cost spikes for manufacturers and end consumers. Organizations today need to select between absorbing their higher expenses and shifting these costs to their customers because current elevated tariffs apply to finished goods and raw materials, resulting in lower market effectiveness. The economic effects of U.S. import changes have generated difficulties for developing countries that rely heavily on American products, so these nations have begun to change their trading approaches and discover fresh supply chain options. The implementation of new tariffs has both encouraged local production development and produced financial challenges for small enterprises to handle their debts. The new policy introduces market instability that lowers growth trajectories while it demands that business stakeholders make strategic adjustments for the altered trade conditions.

Key Players Landscape and Outlook

The leading participants within the oral protein and peptides sector apply various tactics to enhance their market standing and maintain their long-term sustainability. Companies are investing in research and development alongside strategic partnerships and market expansion efforts to fuel their innovative activities in this sector. Companies protect their competitive position by obtaining exclusive rights through patent registration that enables them to maintain market control. The companies choose to work with local manufacturers in emerging markets to achieve two important objectives, which include lowering costs and expanding treatment availability to more patients.

For instance, in February 2025, Oramed Pharmaceuticals Inc. announced a joint venture with Hefei Tianhui Biotech Co. Ltd. to spin off its Protein Oral Delivery technology, which aims to redefine diabetes care and transform the future of oral biologics and chronic disease management.

For instance, in December 2024, Merck & Co., Inc. and Hansoh Pharma jointly announced that they are entering into a global licensing agreement for HS-10535, an investigational oral GLP-1 receptor agonist.

For instance, in May 2025, Novo Nordisk A/S is preparing to launch its Wegovy, a blockbuster weight loss medication, in the upcoming years 2026 for the treatment of obesity.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Oral Proteins and Peptides Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Active Ingredient
      • 5.2.1.1. Semaglutide
      • 5.2.1.2. Linaclotide
      • 5.2.1.3. Calcitonin
      • 5.2.1.4. Octreotide
      • 5.2.1.5. Others
    • 5.2.2. Formulation Type
      • 5.2.2.1. Tablets
      • 5.2.2.2. Capsules
      • 5.2.2.3. Oral Suspensions/Solutions
    • 5.2.3. By Delivery Technology
      • 5.2.3.1. Enteric Coating Systems
      • 5.2.3.2. Nanoparticle/Carrier-Based Delivery
      • 5.2.3.3. Mucoadhesive Technologies
      • 5.2.3.4. Others
    • 5.2.4. By Therapeutic Indication
      • 5.2.4.1. Diabetes Mellitus
      • 5.2.4.2. Gastrointestinal Disorders
      • 5.2.4.3. Bone Metabolic Diseases
      • 5.2.4.4. Endocrine Disorders
      • 5.2.4.5. Genetic and Rare Diseases
      • 5.2.4.6. Others
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Active Ingredient
    • 5.3.2. By Formulation Type
    • 5.3.3. By Delivery Technology
    • 5.3.4. By Therapeutic Indication
    • 5.3.5. By Region

6. North America Oral Proteins and Peptides Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Active Ingredient
      • 6.2.1.1. Semaglutide
      • 6.2.1.2. Linaclotide
      • 6.2.1.3. Calcitonin
      • 6.2.1.4. Octreotide
      • 6.2.1.5. Others
    • 6.2.2. Formulation Type
      • 6.2.2.1. Tablets
      • 6.2.2.2. Capsules
      • 6.2.2.3. Oral Suspensions/Solutions
    • 6.2.3. By Delivery Technology
      • 6.2.3.1. Enteric Coating Systems
      • 6.2.3.2. Nanoparticle/Carrier-Based Delivery
      • 6.2.3.3. Mucoadhesive Technologies
      • 6.2.3.4. Others
    • 6.2.4. By Therapeutic Indication
      • 6.2.4.1. Diabetes Mellitus
      • 6.2.4.2. Gastrointestinal Disorders
      • 6.2.4.3. Bone Metabolic Diseases
      • 6.2.4.4. Endocrine Disorders
      • 6.2.4.5. Genetic and Rare Diseases
      • 6.2.4.6. Others
    • 6.2.5. By Country Share
      • 6.2.5.1. United States
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Oral Proteins and Peptides Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Active Ingredient
          • 6.3.1.2.1.1. Semaglutide
          • 6.3.1.2.1.2. Linaclotide
          • 6.3.1.2.1.3. Calcitonin
          • 6.3.1.2.1.4. Octreotide
          • 6.3.1.2.1.5. Others
        • 6.3.1.2.2. By Formulation Type
          • 6.3.1.2.2.1. Tablets
          • 6.3.1.2.2.2. Capsules
          • 6.3.1.2.2.3. Oral Suspensions/Solutions
        • 6.3.1.2.3. By Delivery Technology
          • 6.3.1.2.3.1. Enteric Coating Systems
          • 6.3.1.2.3.2. Nanoparticle/Carrier-Based Delivery
          • 6.3.1.2.3.3. Mucoadhesive Technologies
          • 6.3.1.2.3.4. Others
        • 6.3.1.2.4. By Therapeutic Indication
          • 6.3.1.2.4.1. Diabetes Mellitus
          • 6.3.1.2.4.2. Gastrointestinal Disorders
          • 6.3.1.2.4.3. Bone Metabolic Diseases
          • 6.3.1.2.4.4. Endocrine Disorders
          • 6.3.1.2.4.5. Genetic and Rare Diseases
          • 6.3.1.2.4.6. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Oral Proteins and Peptides Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Oral Proteins and Peptides Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Oral Proteins and Peptides Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Oral Proteins and Peptides Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Supply Chain Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

  • 17.1. Market Drivers
  • 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

  • 19.1. Regulatory Approval Scenario
  • 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

  • 22.1. Competition Matrix of Top 5 Market Leaders
  • 22.2. SWOT Analysis for Top 5 Players
  • 22.3. Key Players Landscape for Top 10 Market Players
    • 22.3.1. Novo Nordisk A/S
      • 22.3.1.1. Company Details
      • 22.3.1.2. Key Management Personnel
      • 22.3.1.3. Products and Services
      • 22.3.1.4. Financials (As Reported)
      • 22.3.1.5. Key Market Focus and Geographical Presence
      • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 22.3.2. Pfizer Inc.
    • 22.3.3. AbbVie Inc.
    • 22.3.4. Merck & Co., Inc.
    • 22.3.5. Johnson & Johnson Services, Inc.
    • 22.3.6. Biocon Limited
    • 22.3.7. Synergy Pharmaceuticals Inc.
    • 22.3.8. Oramed Pharmaceuticals Inc.
    • 22.3.9. Acadia Pharmaceuticals Inc.
    • 22.3.10. Proxima Concepts Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer